Table 5.
Serum uric acid lowering effects by eGFR at the baseline
| eGFRa category | Dotinurad | Benzbromarone | ||||
|---|---|---|---|---|---|---|
| n | Percent change ± SDb (95% CI) | Achievement ratec (95% CI) | n | Percent change ± SDb (95% CI) | Achievement ratec (95% CI) | |
| Moderate | 32 |
46.8 ± 11.9 (42.56–51.16) |
84.38 (27/32) (67.21–94.72) |
30 |
41.6 ± 12.7 (36.94–46.43) |
83.33 (25/30) (65.28–94.36) |
| Mild | 69 |
45.9 ± 11.5 (43.14–48.69) |
88.41 (61/69) (78.43–94.86) |
67 |
44.9 ± 11.4 (42.12–47.72) |
83.58 (56/67) (72.52–91.51) |
| Normal | 1 | 16.0 |
0 (0/1) (0.00–97.50) |
1 | 38.8 |
100.00 (1/1) (2.50–100.00) |
aeGFR category, normal: eGFR ≥ 90 mL/min/1.73 m2, mild: eGFR ≥ 60 to < 90 mL/min/1.73 m2, moderate: eGFR ≥ 30 to < 60 mL/min/1.73 m2
bPercent change in serum uric acid level from the baseline to the final visit
cPercentage of patients with serum uric acid level ≤ 6.0 mg/dL at the final visit
SD: standard deviation; 95% CI: 95% confidence interval